Cargando…
B Cells and Tertiary Lymphoid Structures: Friends or Foes in Cancer Immunotherapy?
Tumor cells pose a challenge to the adaptive immune system, and its key cell types, T and B cells, have frequently been associated with an improved prognosis. The success of immune checkpoint blockade has confirmed the relevance of T cells. However, the role of B cells is increasingly recognized, an...
Autores principales: | Lauss, Martin, Donia, Marco, Svane, Inge Marie, Jönsson, Göran |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Association for Cancer Research
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9306440/ https://www.ncbi.nlm.nih.gov/pubmed/34965949 http://dx.doi.org/10.1158/1078-0432.CCR-21-1130 |
Ejemplares similares
-
Editorial: Innate Lymphoid Cells in Cancer: Friends or Foes?
por: Jacquelot, Nicolas, et al.
Publicado: (2021) -
Ferroptosis: friend or foe in cancer immunotherapy?
por: Demuynck, Robin, et al.
Publicado: (2023) -
Intratumoral T-cell and B-cell receptor architecture associates with distinct immune tumor microenvironment features and clinical outcomes of anti-PD-1/L1 immunotherapy
por: Schina, Aimilia, et al.
Publicado: (2023) -
Interleukin-21 in cancer immunotherapy: Friend or foe?
por: Stolfi, Carmine, et al.
Publicado: (2012) -
Adrenergic Signaling in Immunotherapy of Cancer: Friend or Foe?
por: Jensen, Agnete Witness Praest, et al.
Publicado: (2021)